Endocrine PathologyPub Date : 2024-06-01Epub Date: 2024-03-05DOI: 10.1007/s12022-024-09806-3
Ozgur Mete, Mehmet Kefeli, Ralph Gilbert, Abha A Gupta
{"title":"Uncommon Mimicker of a High-Grade Thyroid Carcinoma: Solitary Thyroid Metastasis of Gastrointestinal Stromal Tumor (GIST).","authors":"Ozgur Mete, Mehmet Kefeli, Ralph Gilbert, Abha A Gupta","doi":"10.1007/s12022-024-09806-3","DOIUrl":"10.1007/s12022-024-09806-3","url":null,"abstract":"","PeriodicalId":55167,"journal":{"name":"Endocrine Pathology","volume":" ","pages":"154-157"},"PeriodicalIF":11.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140029626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endocrine PathologyPub Date : 2024-06-01Epub Date: 2024-05-27DOI: 10.1007/s12022-024-09810-7
Saltanat Ualiyeva, Maharshi Panchal, Atreyee Basu, Arthur S Tischler
{"title":"\"Strumal Carcinoid\": A Well-Described but Unexplained Intratumoral Tumor.","authors":"Saltanat Ualiyeva, Maharshi Panchal, Atreyee Basu, Arthur S Tischler","doi":"10.1007/s12022-024-09810-7","DOIUrl":"10.1007/s12022-024-09810-7","url":null,"abstract":"","PeriodicalId":55167,"journal":{"name":"Endocrine Pathology","volume":" ","pages":"158-160"},"PeriodicalIF":11.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141155431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endocrine PathologyPub Date : 2024-06-01Epub Date: 2024-03-12DOI: 10.1007/s12022-024-09807-2
Silvia Uccella
{"title":"Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?","authors":"Silvia Uccella","doi":"10.1007/s12022-024-09807-2","DOIUrl":"10.1007/s12022-024-09807-2","url":null,"abstract":"<p><p>In the last two decades, the increasing availability of technologies for molecular analyses has allowed an insight in the genomic alterations of neuroendocrine neoplasms (NEN) of the gastrointestinal tract and pancreas. This knowledge has confirmed, supported, and informed the pathological classification of NEN, clarifying the differences between neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) and helping to define the G3 NET category. At the same time, the identification genomic alterations, in terms of gene mutation, structural abnormalities, and epigenetic changes differentially involved in the pathogenesis of NEC and NET has identified potential molecular targets for precision therapy. This review critically recapitulates the available molecular features of digestive NEC and NET, highlighting their correlates with pathological aspects and clinical characteristics of these neoplasms and revising their role as predictive biomarkers for targeted therapy. In this context, the feasibility and applicability of a molecular classification of gastrointestinal and pancreatic NEN will be explored.</p>","PeriodicalId":55167,"journal":{"name":"Endocrine Pathology","volume":" ","pages":"91-106"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11176254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140112265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endocrine PathologyPub Date : 2024-06-01Epub Date: 2024-02-26DOI: 10.1007/s12022-024-09802-7
Aziz Chouchane, Philipp Kirchner, Ilaria Marinoni, Eva Sticová, Tomáš Jirásek, Aurel Perren
{"title":"Pancreatic Neuroendocrine Microtumors (WHO 2022) Are Not Always Low-Grade Neoplasms: A Case with a Highly Increased Proliferation Rate.","authors":"Aziz Chouchane, Philipp Kirchner, Ilaria Marinoni, Eva Sticová, Tomáš Jirásek, Aurel Perren","doi":"10.1007/s12022-024-09802-7","DOIUrl":"10.1007/s12022-024-09802-7","url":null,"abstract":"<p><p>Traditionally considered non-functional low proliferative benign neuroendocrine proliferations measuring less than 5 mm, pancreatic (neuro)endocrine microadenomas are now classified as pancreatic neuroendocrine microtumors in the 2022 WHO classification of endocrine and neuroendocrine tumors. This case report discussed the features of an incidentally identified 4.7-mm glucagon-expressing pancreatic neuroendocrine microtumor with MEN1 mutation only, chromosomally stable and an epigenetic alpha-like phenotype. The tumor was associated with an unexplained increased proliferation rate in Ki-67 of 15%. There was no associated DAXX/ATRX deficiency. The presented case challenges the conventional thought of a low proliferative disease of the so-called \"pancreatic neuroendocrine microadenomas\" and provides additional support to the 2022 WHO classification that also requires grading of these neoplasms. Despite exhibiting molecular features of less aggressive behavior, the case also underscores the biological complexity of pancreatic neuroendocrine microtumors. By recognizing the heterogenous spectrum of neuroendocrine neoplasms, the current case also contributes to ongoing discussions on how to optimize the clinical management of such tumors.</p>","PeriodicalId":55167,"journal":{"name":"Endocrine Pathology","volume":" ","pages":"147-153"},"PeriodicalIF":11.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11176210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139974725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endocrine PathologyPub Date : 2024-06-01Epub Date: 2024-06-04DOI: 10.1007/s12022-024-09813-4
Ozgur Mete, David W Dodington, Daniel L Shen, Sylvia L Asa
{"title":"The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors.","authors":"Ozgur Mete, David W Dodington, Daniel L Shen, Sylvia L Asa","doi":"10.1007/s12022-024-09813-4","DOIUrl":"10.1007/s12022-024-09813-4","url":null,"abstract":"<p><p>Appendiceal neuroendocrine tumors (NETs) are common and often are identified as incidental lesions at the time of appendectomy. The guidelines for management are based on tumor size, degree of invasion, and the Ki67 proliferation index. Most small bowel NETs are composed of serotonin-producing EC-cells, but there are multiple other neuroendocrine cell types. In the rectum, there are L-cell tumors that express peptide YY (PYY), glucagon-like peptides (GLPs), and pancreatic polypeptide (PP); they are thought to have a better prognosis than serotonin-producing tumors. We investigated whether the appendix has distinct neuroendocrine tumor types based on cell type and whether that distinction has clinical significance. We collected 135 appendiceal NETs from the pathology archives of UHN Toronto and UHCMC (Cleveland). We analyzed the expression of biomarkers including CDX2, SATB2, PSAP, serotonin, glucagon (that detects GLPs), PYY, and pancreatic polypeptide (PP) and correlated the results with clinicopathologic parameters. Immunohistochemistry identified three types of appendiceal NETs. There were 75 (56%) classified as EC-cell tumors and 37 (27%) classified as L-cell tumors; the remaining 23 (17%) expressed serotonin and one of the L-cell biomarkers and were classified as mixed. EC-cell tumors were significantly larger with more extensive invasion involving the muscularis propria, subserosa, and mesoappendix compared with L-cell tumors. Mixed tumors were intermediate in all of these parameters. Both EC-cell and mixed tumors had lymphatic and/or vascular invasion while L-cell tumors had none. Unlike EC-cell NETs, L-cell tumors were not associated with lymph node metastasis. Tumor type correlated with pT stage and the only patient with distant metastatic disease in this series had an EC-cell tumor. Our study confirms that appendiceal NETs are not a homogeneous tumor population. There are at least three types of appendiceal NET, including EC-cell, L-cell, and mixed tumors. This information is important for surveillance of patients, as monitoring urinary 5HIAA levels is only appropriate for patients with serotonin-producing tumors, whereas measurement of GLPs and/or PP is more appropriate for patients with L-cell tumors. Our data also show that tumor type is of significance with EC-cell tumors exhibiting the most aggressive behavior.</p>","PeriodicalId":55167,"journal":{"name":"Endocrine Pathology","volume":" ","pages":"107-112"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11176202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinicopathologic Features and Cytologic Correlation of ALK-Rearranged Papillary Thyroid Carcinoma: A Series of Eight Cases","authors":"Kun-Ping Shih, Yu-Cheng Lee, Jia-Jiun Tsai, Shu-Hui Lin, Chih-Yi Liu, Wan-Shan Li, Chien-Feng Li, Jen-Fan Hang","doi":"10.1007/s12022-024-09808-1","DOIUrl":"https://doi.org/10.1007/s12022-024-09808-1","url":null,"abstract":"<p><i>Anaplastic lymphoma kinase</i> (<i>ALK</i>) gene fusions are rare in papillary thyroid carcinoma (PTC) but may serve as a therapeutic target. This study aims to evaluate the preoperative cytologic findings and clinicopathologic features of a series of eight <i>ALK</i>-rearranged PTCs from our pathology archives and consultations. All cases were confirmed by ALK D5F3 immunohistochemistry and six with additional targeted RNA-based next-generation sequencing (NGS). The original fine-needle aspiration (FNA) cytology diagnosis included the Bethesda System (TBS) category II in three (37.5%), TBS III in two (25%), TBS V in two (25%), and TBS VI in one (12.5%). Six cases had available FNA cytology and were reviewed. The cytologic features showed microfollicular architecture as well as limited or reduced nuclear elongation and chromatin alterations in all six. Nuclear grooves and pseudoinclusions were absent in two cases, rarely or focally noted in three, and frequently found in one. Two cases initially diagnosed as TBS II, showing microfollicular architecture without well-developed nuclear features, were revised to TBS III (with architectural atypia only). For histologic correlations, four were infiltrative follicular variant PTCs, three as classic subtype PTC with predominant follicular growth, and one as solid/trabecular subtype PTC. All eight cases demonstrated reduced PTC nuclear features with respect to nuclear elongation and chromatin alterations compared to those typically identified in “<i>BRAF</i>-like” PTCs. The NGS testing revealed <i>EML4::ALK</i> fusion in three, <i>STRN::ALK</i> fusion in two, and <i>ITSN2::ALK</i> fusion in one. In conclusion, although <i>ALK</i>-rearranged PTCs have been associated with neutral gene expression profile from a <i>BRAF-RAS</i> scoring perspective, the “<i>RAS</i>-like” nuclear features were more commonly identified in this series, resulting in frequent indeterminate diagnosis of preoperative FNA.</p>","PeriodicalId":55167,"journal":{"name":"Endocrine Pathology","volume":"44 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140629532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endocrine PathologyPub Date : 2024-03-01Epub Date: 2023-12-14DOI: 10.1007/s12022-023-09794-w
Francesca Carbonara, Tiziana Feola, Francesca Gianno, Michela Anna Polidoro, Rosa Maria Di Crescenzo, Antonietta Arcella, Michelangelo De Angelis, Roberta Morace, Dario de Alcubierre, Vincenzo Esposito, Felice Giangaspero, Marie-Lise Jaffrain-Rea
{"title":"Clinical and Molecular Characteristics of Gonadotroph Pituitary Tumors According to the WHO Classification.","authors":"Francesca Carbonara, Tiziana Feola, Francesca Gianno, Michela Anna Polidoro, Rosa Maria Di Crescenzo, Antonietta Arcella, Michelangelo De Angelis, Roberta Morace, Dario de Alcubierre, Vincenzo Esposito, Felice Giangaspero, Marie-Lise Jaffrain-Rea","doi":"10.1007/s12022-023-09794-w","DOIUrl":"10.1007/s12022-023-09794-w","url":null,"abstract":"<p><p>Since 2017, hormone-negative pituitary neuroendocrine tumors expressing the steroidogenic factor SF1 have been recognized as gonadotroph tumors (GnPT) but have been poorly studied. To further characterize their bio-clinical spectrum, 54 GnPT defined by immunostaining for FSH and/or LH (group 1, n = 41) or SF1 only (group 2, n = 13) were compared and studied for SF1, βFSH, βLH, CCNA2, CCNB1, CCND1, caspase 3, D2R, and AIP gene expression by qRT-PCR. Immunohistochemistry for AIP and/or D2R was performed in representative cases. Overall, patients were significantly younger in group 1 (P = 0.040 vs group 2), with a similar trend excluding recurrent cases (P = 0.078), and no significant difference in gender, tumor size, invasion or Ki67. SF1 expression was similar in both groups but negatively correlated with the patient's age (P = 0.013) and positively correlated with βLH (P < 0.001) expression. Beta-FSH and AIP were significantly higher in group 1 (P = 0.042 and P = 0.024, respectively). Ki67 was unrelated to gonadotroph markers but positively correlated with CCNB1 (P = 0.001) and negatively correlated with CCND1 (P = 0.008). D2R and AIP were strongly correlated with each other (P < 0.001), and both positively correlated with SF1, βFSH, βLH, and CCND1. AIP immunopositivity was frequently observed in both groups, with a similar median score, and unrelated to Ki67. D2R immunostaining was best detected with a polyclonal antibody and mostly cytoplasmic. This study indicates that hormone-negative GnPT tend to occur in older patients but do not significantly differ from other GnPT in terms of invasion or proliferation. It also points out the current limits of D2R immunostaining in such tumors.</p>","PeriodicalId":55167,"journal":{"name":"Endocrine Pathology","volume":" ","pages":"1-13"},"PeriodicalIF":4.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endocrine PathologyPub Date : 2024-03-01Epub Date: 2024-01-22DOI: 10.1007/s12022-024-09799-z
Rumeal D Whaley, Lori A Erickson
{"title":"Thyroid Gland Blastomycosis.","authors":"Rumeal D Whaley, Lori A Erickson","doi":"10.1007/s12022-024-09799-z","DOIUrl":"10.1007/s12022-024-09799-z","url":null,"abstract":"","PeriodicalId":55167,"journal":{"name":"Endocrine Pathology","volume":" ","pages":"82-83"},"PeriodicalIF":4.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139514303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endocrine PathologyPub Date : 2024-03-01Epub Date: 2023-11-30DOI: 10.1007/s12022-023-09795-9
C Christofer Juhlin, Zubair W Baloch
{"title":"The 3<sup>rd</sup> Edition of Bethesda System for Reporting Thyroid Cytopathology: Highlights and Comments.","authors":"C Christofer Juhlin, Zubair W Baloch","doi":"10.1007/s12022-023-09795-9","DOIUrl":"10.1007/s12022-023-09795-9","url":null,"abstract":"","PeriodicalId":55167,"journal":{"name":"Endocrine Pathology","volume":" ","pages":"77-79"},"PeriodicalIF":4.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138464554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}